Island Pharmaceuticals Advances Marburg Virus Treatment with Texas Biomed Partnership
Table of Contents
Island Pharmaceuticals (ASX:ILA) has entered a master service agreement with the Texas Biomedical Research Institute, a critical step toward potential FDA approval of its lead antiviral molecule, galidesivir, for the treatment of the deadly Marburg virus. The collaboration focuses on leveraging the institute’s specialized facilities for potential non-human primate studies under the FDA’s Animal Rule pathway.
The Animal rule allows for approval of medical products when human trials are not feasible or ethical, relying instead on well-defined and reproducible data from animal studies. This pathway was recently deemed appropriate for Marburg countermeasures, accelerating the potential timeline for galidesivir’s progress.
Texas Biomed: A Leading Research Center
Established in 1941, Texas Biomed stands as a federally designated National Primate Research Centre. It is one of only four Biosafety Level 4 (BSL-4) facilities in the United States authorized to conduct pre-clinical infectious disease research utilizing non-human primates. Notably, Texas Biomed is the sole independant, non-profit research institute in the US that combines the highest level of biocontainment laboratories with dedicated biodefence research capabilities.
BSL-4 represents the most stringent level of biosecurity,requiring rigorous protocols for handling dangerous and exotic pathogens. These pathogens lack available vaccines or treatments and pose a significant risk of severe, potentially fatal disease in humans.
building on a Strong Foundation
Island’s decision to partner with Texas Biomed followed thorough due diligence,recognizing the institute’s proven track record in infectious disease research.This includes prior successful non-human primate studies focused on lethal pathogens, including those causing hemorrhagic-fever viruses.
According to a company release, Texas Biomed’s unique infrastructure – encompassing BSL-4 containment, extensive non-human primate resources, and deep regulatory expertise – will provide “exceptional optionality” for the planned development of galidesivir. The agreement also positions Island to potentially benefit from a Priority Review Voucher post-approval, further expediting the process.
FDA Collaboration and Future Plans
Island Pharmaceuticals anticipates receiving further guidance from the FDA in the coming months. This feedback will be instrumental in refining the proposed study design before initiating a planned clinical program.
“Texas biomed’s world-class expertise provides us with an optimal potential partner to progress this antiviral candidate toward FDA approval,” stated Dr. David Foster, Island managing director. “Its BSL-4 capabilities and access to a National Primate Research Centre have the potential to efficiently generate data to underpin approval under the Animal Rule pathway, once our clinical trial program has been finalised.”
Dr. Foster also indicated that Island will cont
Here’s a breakdown answering the “Why, Who, What, and How” questions:
* Why: Island Pharmaceuticals is pursuing FDA approval for galidesivir to address the urgent need for a treatment against the deadly Marburg virus, for which there are currently no approved therapies.
* Who: Island Pharmaceuticals (ASX:ILA) is partnering with the Texas Biomedical Research Institute (Texas Biomed). Key individuals include Dr. David Foster, island’s managing director.
* What: Island Pharmaceuticals has entered a master service agreement with Texas Biomed to conduct non-human primate studies of galidesivir, leveraging the FDA’s Animal Rule pathway for potential approval.
* how did it end? The agreement is a starting point for potential FDA approval. Island Pharmaceuticals anticipates further guidance from the FDA to refine study design and initiate a clinical program. The process is ongoing, with the potential for expedited review via a Priority Review Voucher
